Kurv Yield Prem Strategy Tesla ETF (TSLP)
| Assets | $21.97M |
| Expense Ratio | 1.00% |
| PE Ratio | 120.49 |
| Shares Out | 920,000 |
| Dividend (ttm) | $8.75 |
| Dividend Yield | 36.20% |
| Ex-Dividend Date | Dec 3, 2025 |
| Payout Ratio | 4,366.85% |
| 1-Year Return | -15.08% |
| Volume | 10,507 |
| Open | 24.17 |
| Previous Close | 24.10 |
| Day's Range | 24.12 - 24.18 |
| 52-Week Low | 15.36 |
| 52-Week High | 34.29 |
| Beta | 1.36 |
| Holdings | 10 |
| Inception Date | Oct 27, 2023 |
About TSLP
Fund Home PageThe Kurv Yield Prem Strategy Tesla ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.
Top 10 Holdings
100.00% of assets| Name | Symbol | Weight |
|---|---|---|
| United States Treasury Bills 0% | B.0 03.19.26 | 37.83% |
| United States Treasury Bills 0% | B.0 12.26.25 | 26.34% |
| United States Treasury Bills 0% | B.0 06.11.26 | 24.57% |
| Tsla 12/19/2025 390 C | n/a | 21.99% |
| Fidelity Government Portfolio | FIGXX | 2.79% |
| OTHER ASSETS AND LIABILITIES | n/a | 0.01% |
| US DOLLARS | n/a | -0.08% |
| Tsla 12/05/2025 440 C | n/a | -1.11% |
| Cash Offset | n/a | -2.04% |
| Tsla 12/19/2025 390 P | n/a | -10.29% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 3, 2025 | $0.500 | Dec 4, 2025 |
| Nov 5, 2025 | $0.500 | Nov 6, 2025 |
| Oct 8, 2025 | $0.500 | Oct 9, 2025 |
| Sep 3, 2025 | $0.450 | Sep 4, 2025 |
| Aug 6, 2025 | $0.450 | Aug 7, 2025 |
| Jul 2, 2025 | $0.450 | Jul 3, 2025 |
News
Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Su...
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...